A ten-week active-comparator trial found large anxiety-score reductions in both groups. It tested a particular standardized extract, not all products containing the same plant.
Romero-Cerecero and colleagues enrolled 167 patients with moderate or severe generalized anxiety disorder. Participants received a galphimine-B-standardized Galphimia glauca extract or alprazolam under double-blind randomized conditions.
Hamilton Anxiety scores fell markedly in both groups. The reported comparison did not find a significant efficacy difference, while daytime sleepiness was reported less often with the extract than with alprazolam.
Without a placebo group, the study cannot independently quantify how much of each group’s improvement arose from nonspecific effects. A nonsignificant difference is also not automatically a formal demonstration of equivalence.
The standardized preparation, selected population, and ten-week duration restrict application to other supplements, long-term use, or rare toxicities. Daytime sleepiness is one tolerability outcome rather than a comprehensive safety assessment.
Identify the exact preparation and endpoint. The paper supports a limited comparative account of symptoms and reported sleepiness; it does not establish that botanical products are generally safer, interchangeable with prescription medicine, or free of interactions and impairment.
Original analysis of the supplied journal article, identified as PMC6374797.